The present invention is generally directed to a treatment of Chronic Obstructive Pulmonary Disease (COPD). The present invention is more particularly directed to removable air passageway obstruction devices, and systems and methods for removing the devices.
Chronic Obstructive Pulmonary Disease (COPD) has become a major cause of morbidity and mortality in the United States over the last three decades. COPD is characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema. The airflow obstruction in COPD is due largely to structural abnormalities in the smaller airways. Important causes are inflammation, fibrosis, goblet cell metaplasia, and smooth muscle hypertrophy in terminal bronchioles.
The incidence, prevalence, and health-related costs of COPD are on the rise. Mortality due to COPD is also on the rise. In 1991 COPD was the fourth leading cause of death in the United States and had increased 33% since 1979.
COPD affects the patients whole life. It has three main symptoms: cough; breathlessness; and wheeze. At first, breathlessness may be noticed when running for a bus, digging in the garden, or walking up hill. Later, it may be noticed when simply walking in the kitchen. Over time, it may occur with less and less effort until it is present all of the time.
COPD is a progressive disease and currently has no cure. Current treatments for COPD include the prevention of further respiratory damage, pharmacotherapy, and surgery. Each is discussed below.
The prevention of further respiratory damage entails the adoption of a healthy lifestyle. Smoking cessation is believed to be the single most important therapeutic intervention. However, regular exercise and weight control are also important. Patients whose symptoms restrict their daily activities or who otherwise have an impaired quality of life may require a pulmonary rehabilitation program including ventilatory muscle training and breathing retraining. Long-term oxygen therapy may also become necessary.
Pharmacotherapy may include bronchodilator therapy to open up the airways as much as possible or inhaled .beta.-agonists. For those patients who respond poorly to the foregoing or who have persistent symptoms, Ipratropium bromide may be indicated. Further, courses of steroids, such as corticosteroids, may be required. Lastly, antibiotics may be required to prevent infections and influenza and pneumococcal vaccines may be routinely administered. Unfortunately, there is no evidence that early, regular use of pharmacotherapy will alter the progression of COPD.
About 40 years ago, it was first postulated that the tethering force that tends to keep the intrathoracic airways open was lost in emphysema and that by surgically removing the most affected parts of the lungs, the force could be partially restored. Although the surgery was deemed promising, the procedure was abandoned.
The lung volume reduction surgery (LVRS) was later revived. In the early 1990's, hundreds of patients underwent the procedure. However, the procedure has fallen out of favor due to the fact that Medicare stopping reimbursing for LVRS. Unfortunately, data is relatively scarce and many factors conspire to make what data exists difficult to interpret. The procedure is currently under review in a controlled clinical trial. What data does exist tends to indicate that patients benefited from the procedure in terms of an increase in forced expiratory volume, a decrease in total lung capacity, and a significant improvement in lung function, dyspnea, and quality of life. However, the surgery is not without potential complications. Lung tissue is very thin and fragile. Hence, it is difficult to suture after sectioning. This gives rise to potential infection and air leaks. In fact, nearly thirty percent (30%) of such surgeries result in air leaks.
Improvements in pulmonary function after LVRS have been attributed to at least four possible mechanisms. These include enhanced elastic recoil, correction of ventilation/perfusion mismatch, improved efficiency of respiratory musculature, and improved right ventricular filling.
Lastly, lung transplantation is also an option. Today, COPD is the most common diagnosis for which lung transplantation is considered. Unfortunately, this consideration is given for only those with advanced COPD. Given the limited availability of donor organs, lung transplant is far from being available to all patients.
In view of the need in the art for new and improved therapies for COPD which provide more permanent results than pharmacotherapy while being less invasive and traumatic than LVRS, at least two new therapies have recently been proposed.
Both of these new therapies provide lung size reduction by permanently collapsing at least a portion of a lung.
In accordance with a first one of these therapies, and as described in U.S. Pat. No. 6,258,100 assigned to the assignee of the present invention and incorporated herein by reference, a lung may be collapsed by obstructing an air passageway communicating with the lung portion to be collapsed. The air passageway may be obstructed by placing an obstructing member in the air passageway. The obstructing member may be a plug-like device which precludes air flow in both directions or a one-way valve which permits air to be exhaled from the lung portion to be collapsed while precluding air from being inhaled into the lung portion. Once the air passageway is sealed, the residual air within the lung will be absorbed over time to cause the lung portion to collapse.
As further described in U.S. Pat. No. 6,258,100, the lung portion may be collapsed by inserting a conduit into the air passageway communicating with the lung portion to be collapsed. An obstruction device, such as a one-way valve is then advanced down the conduit into the air passageway. The obstruction device is then deployed in the air passageway for sealing the air passageway and causing the lung portion to be collapsed.
The second therapy is fully described in copending U.S. application Ser. No. 09/534,244, filed Mar. 23, 2000, for LUNG CONSTRICTION APPARATUS AND METHOD and, is also assigned to the assignee of the present invention. As described therein, a lung constriction device including a sleeve of elastic material is configured to cover at least a portion of a lung. The sleeve has a pair of opened ends to permit the lung portion to be drawn into the sleeve. Once drawn therein, the lung portion is constricted by the sleeve to reduce the size of the lung portion.
Both therapies hold great promise for treating COPD. Neither therapy requires sectioning and suturing of lung tissue.
While either therapy alone would be effective in providing lung size reduction and treatment of COPD, it has recently been proposed that the therapies may be combined for more effective treatment. More specifically, it has been proposed that the therapies could be administered in series, with the first mentioned therapy first applied acutely for evaluation of the effectiveness of lung size reduction in a patient and which lung portions should be reduced in size to obtain the best results. The first therapy is ideal for this as it is noninvasive and could be administered in a physician's office. Once the effectiveness of lung size reduction is confirmed and the identity of the lung portions to be collapsed is determined, the more invasive second mentioned therapy may be administered.
In order to combine these therapies, or simply administer the first therapy for evaluation, it will be necessary for at least some of the deployed air passageway obstruction devices to be removable. Unfortunately, such devices as currently known in the art are not suited for removal. While such devices are expandable for permanent deployment, such devices are not configured or adapted for recollapse after having once been deployed in an air passageway to facilitate removal. Hence, there is a need in the art for air passageway obstruction devices which are removable after having been deployed and systems and methods for removing them.
The invention provides device for reducing the size of a lung comprising an obstructing structure dimensioned for insertion into an air passageway communicating with a portion of the lung to be reduced in size, the obstructing structure having an outer dimension which is so dimensioned when deployed in the air passageway to preclude air from flowing into the lung portion to collapse the portion of the lung for reducing the size of the lung, the obstructing structure being collapsible to permit removal of the obstruction device from the air passageway.
The invention further provides an assembly comprising a device for reducing the size of a lung, the device being dimensioned for insertion into an air passageway communicating with a portion of the lung to be reduced in size, the device having an outer dimension which is so dimensioned when deployed in the air passageway to preclude air from flowing into the lung portion to collapse the portion of the lung for reducing the size of the lung, a catheter having an internal lumen and being configured to be passed down a trachea, into the air passageway, and a retractor dimensioned to be passed down the internal lumen of the catheter, seizing the device, and pulling the obstruction device proximally into the internal lumen to remove the device from the air passageway. The device is collapsible after having been deployed to permit the device to be pulled proximally into the internal lumen of the catheter by the retractor.
The invention further provides a method of removing a deployed air passageway obstruction device from an air passageway in which the device is deployed. The method includes the steps of passing a catheter, having an internal lumen, down a trachea and into the air passageway, advancing a retractor down the internal lumen of the catheter to the device, seizing the device with the retractor, collapsing the device to free the device from deployment in the air passageway, and pulling the device with the retractor proximally into the internal lumen of the catheter.
The invention still further provides an air passageway obstruction device comprising a frame structure, and a flexible membrane overlying the frame structure. The frame structure is collapsible upon advancement of the device into the air passageway, expandable into a rigid structure upon deployment in the air passageway whereby the flexible membrane obstructs inhaled air flow into a lung portion communicating with the air passageway, and re-collapsible upon removal from the air passageway.
The invention still further provides an air passageway obstruction device comprising frame means for forming a support structure, and flexible membrane means overlying the support structure. The frame means is expandable to an expanded state within an air passageway to position the membrane means for obstructing air flow within the air passageway and is collapsible for removal of the device from the air passageway.
The features of the present invention which are believed to be novel are set forth with particularity in the appended claims. The invention, together with further objects and advantages thereof, may best be understood by making reference to the following description taken in conjunction with the accompanying drawings, in the several figures of which like referenced numerals identify identical elements, and wherein:
Referring now to
The respiratory system 20 includes the trachea 28, the left mainstem bronchus 30, the right mainstem bronchus 32, the bronchial branches 34, 36, 38, 40, and 42 and sub-branches 44, 46, 48, and 50. The respiratory system 20 further includes left lung lobes 52 and 54 and right lung lobes 56, 58, and 60. Each bronchial branch and sub-branch communicates with a respective different portion of a lung lobe, either the entire lung lobe or a portion thereof. As used herein, the term “air passageway” is meant to denote either a bronchial branch or sub-branch which communicates with a corresponding individual lung lobe or lung lobe portion to provide inhaled air thereto or conduct exhaled air therefrom.
Characteristic of a healthy respiratory system is the arched or inwardly arcuate diaphragm 26. As the individual inhales, the diaphragm 26 straightens to increase the volume of the thorax 22. This causes a negative pressure within the thorax. The negative pressure within the thorax in turn causes the lung lobes to fill with air. When the individual exhales, the diaphragm returns to its original arched condition to decrease the volume of the thorax. The decreased volume of the thorax causes a positive pressure within the thorax which in turn causes exhalation of the lung lobes.
In contrast to the healthy respiratory system of
In accordance with this embodiment of the present invention, COPD treatment or evaluation is initiated by feeding a conduit or catheter 70 down the trachea 28, into a mainstream bronchus such as the right mainstem bronchus 32, and into an air passageway such as the bronchial branch 42 or the bronchial sub-branch 50. An air passageway obstruction device embodying the present invention is then advanced down an internal lumen 71 of the catheter 70 for deployment in the air passageway. Once deployed, the obstruction device precludes inhaled air from entering the lung portion to be collapsed. In accordance with the present invention, it is preferable that the obstruction device take the form of a one-way valve. In addition to precluding inhaled air from entering the lung portion, the device further allows air within the lung portion to be exhaled. This results in more rapid collapse of the lung portion. However, obstruction devices which preclude both inhaled and exhaled air flow are contemplated as falling within the scope of the invention.
The catheter 70 is preferably formed of flexible material such as polyethylene. Also, the catheter 70 is preferably preformed with a bend 72 to assist the feeding of the catheter from the right mainstem bronchus 32 into the bronchial branch 42.
Each of the frame supports has a shape to define a generally cylindrical center portion 94 and a pair of oppositely extending inwardly arcuate conical end portions 96 and 98. The frame structure further includes a plurality of fixation members 100, 102, and 104 which extend distally from the proximal end 82. The fixation members have the generally conical shape and terminate in fixation projections or anchors 106, 108, and 110 which extend radially outwardly.
Overlying and partially enclosing the frame structure 86 is a flexible membrane 112. The flexible membrane extends over the generally cylindrical and conical portions 94 and 98 defined by the frame structure. Hence, the flexible membrane is opened in the proximal direction.
The flexible membrane may be formed of silicone or polyurethane, for example. It may be secured to the frame structure in a manner known in the art such as by crimping, riveting, or adhesion.
The frame structure 86 and the device 80 are illustrated in
When the device 80 is deployed, the frame structure 86 and flexible membrane 112 form an obstructing structure or one-way valve.
As shown in
The device 80 is shown in
In
The device 130 is of similar configuration to the device 80 previously described. Here however, the fixation members 136 and 138 are extensions of the frame supports 132 and 134, respectively. To that end, it will be noted in
When the device is to be removed, the frame structure of the device 130 is held stationary by a retractor within the catheter 70 and the catheter is advanced distally. When the catheter 70 engages the frame supports 132 and 134, the frame supports are deflected inwardly from their dashed line positions to their solid line positions. This also causes the fixation members 136 and 138 to be deflected inwardly from their dashed line positions to their solid line positions in the direction of arrows 154. These actions disengage the device 130 from the inner wall of the air passageway 42. Now, the retractor may pull the device into the internal lumen 71 of the catheter 70 for removal of the device 130 from the air passageway 42.
Since each of the frame supports are identical, only frame support 164 will be described herein. As will be noted, the support 164 includes a bend point 174 with a relatively long section 176 extending distally from the bend point 174 and a relatively short section 178 extending proximally from the bend point 174. The short section 178 includes a fixation projection or anchor 180 extending slightly distally from the bend point 174.
The relatively long sections of the frame supports are covered with a flexible membrane 186 as shown in
While particular embodiments of the present invention have been shown and described, modifications may be made, and it is therefore intended in the appended claims to cover all such changes and modifications which fall within the true spirit and scope of the invention.
This application is a continuation of U.S. application Ser. No. 10/847,554, filed May 17, 2004, which is a divisional of U.S. application Ser. No. 09/951,105, filed Sep. 11, 2001, each of which is hereby incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2832078 | Williams | Apr 1958 | A |
2981254 | Vanderbilt | Apr 1961 | A |
3320972 | High et al. | May 1967 | A |
3445916 | Schulte | May 1969 | A |
3472230 | Forgarty | Oct 1969 | A |
3540431 | Modin-Uddin | Nov 1970 | A |
3617060 | Iezzi | Nov 1971 | A |
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3874388 | King et al. | Feb 1973 | A |
3757783 | Alley | Sep 1973 | A |
3760808 | Bleuer | Sep 1973 | A |
3788327 | Donowitz et al. | Jan 1974 | A |
4014318 | Dockum et al. | Mar 1977 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4084268 | Ionescu et al. | Apr 1978 | A |
4086665 | Poirlier | May 1978 | A |
4212463 | Repinski et al. | Jul 1980 | A |
4218782 | Rygg | Aug 1980 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4250873 | Bonnet | Feb 1981 | A |
4302854 | Runge | Dec 1981 | A |
4339831 | Johnson | Jul 1982 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4681110 | Wiktor | Jul 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4727873 | Mobin-Uddin | Mar 1988 | A |
4732152 | Wallsten et al. | Mar 1988 | A |
4759758 | Gabbay | Jul 1988 | A |
4795449 | Schneider et al. | Jan 1989 | A |
4808183 | Panje | Feb 1989 | A |
4819664 | Nazari | Apr 1989 | A |
4830003 | Wolff et al. | May 1989 | A |
4832680 | Haber et al. | May 1989 | A |
4846836 | Reich | Jul 1989 | A |
4850999 | Planck | Jul 1989 | A |
4852568 | Kensey | Aug 1989 | A |
4877025 | Hanson | Oct 1989 | A |
4934999 | Bader | Jun 1990 | A |
4968294 | Salama | Nov 1990 | A |
4979505 | Cox | Dec 1990 | A |
5061274 | Kensey | Oct 1991 | A |
5116360 | Pinchuk et al. | May 1992 | A |
5116564 | Jansen et al. | May 1992 | A |
5123919 | Sauter et al. | Jun 1992 | A |
5151105 | Kwan-Gett | Sep 1992 | A |
5158548 | Lau et al. | Oct 1992 | A |
5161524 | Evans | Nov 1992 | A |
5283063 | Freeman | Feb 1994 | A |
5304199 | Myers | Apr 1994 | A |
5306234 | Johnson | Apr 1994 | A |
5314473 | Godin | May 1994 | A |
5352240 | Ross | Oct 1994 | A |
5358518 | Camilli | Oct 1994 | A |
5366478 | Brinkerhoff et al. | Nov 1994 | A |
5382261 | Palmaz | Jan 1995 | A |
5392775 | Adkins, Jr. et al. | Feb 1995 | A |
5398844 | Zaslavsky | Mar 1995 | A |
5409019 | Wilk | Apr 1995 | A |
5411507 | Heckele | May 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5413599 | Imachi et al. | May 1995 | A |
5417226 | Juma | May 1995 | A |
5445626 | Gigante | Aug 1995 | A |
5453090 | Martenez et al. | Sep 1995 | A |
5484444 | Braunschweiler et al. | Jan 1996 | A |
5486154 | Kelleher | Jan 1996 | A |
5499995 | Teirstein | Mar 1996 | A |
5500014 | Quijano et al. | Mar 1996 | A |
5507754 | Green et al. | Apr 1996 | A |
5507797 | Suzuki | Apr 1996 | A |
5509900 | Kirkman | Apr 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5549628 | Cooper et al. | Aug 1996 | A |
5562608 | Sekins et al. | Oct 1996 | A |
5562728 | Lazarus et al. | Oct 1996 | A |
5603698 | Roberts et al. | Feb 1997 | A |
5645565 | Rudd et al. | Jul 1997 | A |
5660175 | Dayal | Aug 1997 | A |
5662713 | Andersen et al. | Sep 1997 | A |
5669933 | Simon et al. | Sep 1997 | A |
5683451 | Lenker et al. | Nov 1997 | A |
5693089 | Inoue | Dec 1997 | A |
5697968 | Rogers et al. | Dec 1997 | A |
5702343 | Alferness | Dec 1997 | A |
5702409 | Rayburn et al. | Dec 1997 | A |
5725519 | Penner et al. | Mar 1998 | A |
5752965 | Francis et al. | May 1998 | A |
5755770 | Ravenscroft | May 1998 | A |
5797960 | Stevens et al. | Aug 1998 | A |
5800339 | Salama | Sep 1998 | A |
5803078 | Brauner | Sep 1998 | A |
5833694 | Poncet | Nov 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5851232 | Lois | Dec 1998 | A |
5855587 | Hyon | Jan 1999 | A |
5855597 | Jayaraman | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5876445 | Andersen et al. | Mar 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5947997 | Pavcnik et al. | Sep 1999 | A |
5954636 | Schwartz et al. | Sep 1999 | A |
5954766 | Zadno-Azizi et al. | Sep 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5972009 | Fortier et al. | Oct 1999 | A |
5976158 | Adams et al. | Nov 1999 | A |
5976174 | Ruiz | Nov 1999 | A |
5984965 | Knapp et al. | Nov 1999 | A |
6003517 | Sheffield et al. | Dec 1999 | A |
6007575 | Samuels | Dec 1999 | A |
6009614 | Morales | Jan 2000 | A |
6010525 | Bonutti et al. | Jan 2000 | A |
6020380 | Killian | Feb 2000 | A |
6027525 | Suh et al. | Feb 2000 | A |
6045560 | McKean et al. | Apr 2000 | A |
6051022 | Cai et al. | Apr 2000 | A |
6068635 | Gianotti | May 2000 | A |
6068638 | Makower | May 2000 | A |
6077291 | Das | Jun 2000 | A |
6083255 | Laufer et al. | Jul 2000 | A |
6096027 | Layne | Aug 2000 | A |
6099551 | Gabbay | Aug 2000 | A |
6123663 | Rebuffat | Sep 2000 | A |
6132458 | Staehle et al. | Oct 2000 | A |
6135729 | Aber | Oct 2000 | A |
6135991 | Muni et al. | Oct 2000 | A |
6141855 | Morales | Nov 2000 | A |
6149664 | Kurz | Nov 2000 | A |
6162245 | Jayaraman | Dec 2000 | A |
6165179 | Cathcart et al. | Dec 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6174323 | Biggs et al. | Jan 2001 | B1 |
6183520 | Pintauro et al. | Feb 2001 | B1 |
6200333 | Laufer | Mar 2001 | B1 |
6203551 | Wu | Mar 2001 | B1 |
6206918 | Campbell et al. | Mar 2001 | B1 |
6231589 | Wessman et al. | May 2001 | B1 |
6234996 | Bagaoisan et al. | May 2001 | B1 |
6238334 | Easterbrook, III et al. | May 2001 | B1 |
6240615 | Kimes et al. | Jun 2001 | B1 |
6241654 | Alferness | Jun 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6258100 | Alferness et al. | Jul 2001 | B1 |
6267775 | Clerc et al. | Jul 2001 | B1 |
6270527 | Campbell et al. | Aug 2001 | B1 |
6287290 | Perkins et al. | Sep 2001 | B1 |
6287334 | Moll et al. | Sep 2001 | B1 |
6293951 | Alferness et al. | Sep 2001 | B1 |
6302893 | Limon et al. | Oct 2001 | B1 |
6312407 | Zadno-Azizi et al. | Nov 2001 | B1 |
6325777 | Zadno-Azizi et al. | Dec 2001 | B1 |
6325778 | Zadno-Azizi et al. | Dec 2001 | B1 |
6327772 | Zadno-Azizi et al. | Dec 2001 | B1 |
6328689 | Gonzalez et al. | Dec 2001 | B1 |
6355014 | Zadno-Azizi et al. | Mar 2002 | B1 |
6398775 | Perkins et al. | Jun 2002 | B1 |
6402754 | Gonzalez | Jun 2002 | B1 |
6416554 | Alferness et al. | Jul 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6428561 | Johansson-Ruden et al. | Aug 2002 | B1 |
6439233 | Geertsema | Aug 2002 | B1 |
6440164 | DiMatteo et al. | Aug 2002 | B1 |
6447530 | Ostrovsky et al. | Sep 2002 | B1 |
6458076 | Pruitt | Oct 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6471718 | Staehle et al. | Oct 2002 | B1 |
6485407 | Alferness et al. | Nov 2002 | B2 |
6488673 | Laufer | Dec 2002 | B1 |
6491706 | Alferness et al. | Dec 2002 | B1 |
6493589 | Medhkour et al. | Dec 2002 | B1 |
6503272 | Duerig et al. | Jan 2003 | B2 |
6510846 | O'Rourke | Jan 2003 | B1 |
6514290 | Loomas | Feb 2003 | B1 |
6527761 | Soltesz et al. | Mar 2003 | B1 |
6540782 | Snyders | Apr 2003 | B1 |
6544291 | Taylor | Apr 2003 | B2 |
6558429 | Taylor | May 2003 | B2 |
6568387 | Davenport et al. | May 2003 | B2 |
6569166 | Gonzalez | May 2003 | B2 |
6585639 | Kotmel et al. | Jul 2003 | B1 |
6592594 | Rimbaugh et al. | Jul 2003 | B2 |
6599311 | Biggs et al. | Jul 2003 | B1 |
6610043 | Ingenito | Aug 2003 | B1 |
6629951 | Laufer et al. | Oct 2003 | B2 |
6634363 | Danek et al. | Oct 2003 | B1 |
6638285 | Gabbay | Oct 2003 | B2 |
6669724 | Park et al. | Dec 2003 | B2 |
6679264 | Deem et al. | Jan 2004 | B1 |
6682250 | Banks | Jan 2004 | B2 |
6694979 | Deem et al. | Feb 2004 | B2 |
6709401 | Perkins et al. | Mar 2004 | B2 |
6712812 | Roschak et al. | Mar 2004 | B2 |
6722360 | Doshi | Apr 2004 | B2 |
6743259 | Ginn | Jun 2004 | B2 |
6749606 | Keast et al. | Jun 2004 | B2 |
6860847 | Alferness et al. | Mar 2005 | B2 |
6904909 | Andreas et al. | Jun 2005 | B2 |
6941950 | Wilson et al. | Sep 2005 | B2 |
6951571 | Srivastava | Oct 2005 | B1 |
6958076 | Acosta et al. | Oct 2005 | B2 |
6989027 | Allen et al. | Jan 2006 | B2 |
7011094 | Rapacki et al. | Mar 2006 | B2 |
20010010017 | Letac et al. | Jul 2001 | A1 |
20010012949 | Forber | Aug 2001 | A1 |
20010025132 | Alferness et al. | Sep 2001 | A1 |
20010037808 | Deem et al. | Nov 2001 | A1 |
20010041906 | Gonzalez | Nov 2001 | A1 |
20010051799 | Ingenito | Dec 2001 | A1 |
20010052344 | Doshi | Dec 2001 | A1 |
20010056274 | Perkins et al. | Dec 2001 | A1 |
20020007831 | Davenport et al. | Jan 2002 | A1 |
20020052626 | Gilson | May 2002 | A1 |
20020062120 | Perkins et al. | May 2002 | A1 |
20020077593 | Perkins et al. | Jun 2002 | A1 |
20020077696 | Zadno-Azizi et al. | Jun 2002 | A1 |
20020087153 | Roschak et al. | Jul 2002 | A1 |
20020095209 | Zadno-Azizi et al. | Jul 2002 | A1 |
20020111619 | Keast et al. | Aug 2002 | A1 |
20020111620 | Cooper et al. | Aug 2002 | A1 |
20020112729 | DeVore et al. | Aug 2002 | A1 |
20020138135 | Duerig et al. | Sep 2002 | A1 |
20020147462 | Mair et al. | Oct 2002 | A1 |
20030018327 | Truckai et al. | Jan 2003 | A1 |
20030018344 | Kaji et al. | Jan 2003 | A1 |
20030024527 | Ginn | Feb 2003 | A1 |
20030050648 | Alferness et al. | Mar 2003 | A1 |
20030051733 | Kotmel et al. | Mar 2003 | A1 |
20030055331 | Kotmel et al. | Mar 2003 | A1 |
20030070682 | Wilson et al. | Apr 2003 | A1 |
20030083671 | Rimbaugh et al. | May 2003 | A1 |
20030127090 | Gifford et al. | Jul 2003 | A1 |
20030154988 | DeVore et al. | Aug 2003 | A1 |
20030158515 | Gonzalez et al. | Aug 2003 | A1 |
20030167065 | Kumar | Sep 2003 | A1 |
20030180922 | Eaton et al. | Sep 2003 | A1 |
20030181922 | Alferness | Sep 2003 | A1 |
20030183235 | Rimbaugh et al. | Oct 2003 | A1 |
20030195385 | De Vore | Oct 2003 | A1 |
20030212412 | Dillard et al. | Nov 2003 | A1 |
20030216769 | Dillard et al. | Nov 2003 | A1 |
20030228344 | Fields et al. | Dec 2003 | A1 |
20040039250 | Tholfsen et al. | Feb 2004 | A1 |
20040167636 | Dillard et al. | Aug 2004 | A1 |
20040210248 | Gordon et al. | Oct 2004 | A1 |
20040243140 | Alferness et al. | Dec 2004 | A1 |
20050033310 | Alferness et al. | Feb 2005 | A1 |
20050033344 | Dillard et al. | Feb 2005 | A1 |
20050137611 | Escudero et al. | Jun 2005 | A1 |
Number | Date | Country |
---|---|---|
2365752 | Jan 2001 | CA |
2408923 | Nov 2001 | CA |
100 04 979 | Aug 2000 | DE |
1 151 729 | Nov 2001 | EP |
1 157 663 | Nov 2001 | EP |
1 206 276 | May 2002 | EP |
2 324 729 | Nov 1998 | GB |
2 348 138 | Sep 2000 | GB |
2001-583641 | Nov 2001 | JP |
2140211 | Oct 1999 | RU |
852321 | Jul 1981 | SU |
1371700 | Feb 1988 | SU |
1593651 | Sep 1990 | SU |
WO 8809683 | Dec 1988 | WO |
WO 9426175 | Nov 1994 | WO |
WO 9532018 | Nov 1995 | WO |
WO 9634582 | Nov 1996 | WO |
WO 9727893 | Aug 1997 | WO |
WO 9744085 | Nov 1997 | WO |
WO 9800840 | Jan 1998 | WO |
WO 9801084 | Jan 1998 | WO |
WO 9819633 | May 1998 | WO |
PCTUS9818366 | Sep 1998 | WO |
WO 9839047 | Sep 1998 | WO |
WO 9844854 | Oct 1998 | WO |
PCTGB9800652 | Nov 1998 | WO |
WO 9848706 | Nov 1998 | WO |
WO 9901076 | Jan 1999 | WO |
WO 9913801 | Mar 1999 | WO |
WO 9926692 | Jun 1999 | WO |
WO 9932040 | Jul 1999 | WO |
WO 9942059 | Aug 1999 | WO |
WO 9942161 | Aug 1999 | WO |
WO 9959503 | Nov 1999 | WO |
WO 9964109 | Dec 1999 | WO |
WO 0027292 | May 2000 | WO |
WO 0042950 | Jul 2000 | WO |
WO 0051500 | Sep 2000 | WO |
WO 0051510 | Sep 2000 | WO |
WO 0062699 | Oct 2000 | WO |
WO 0078386 | Dec 2000 | WO |
WO 0078407 | Dec 2000 | WO |
PCTUS0018286 | Jan 2001 | WO |
WO 0102042 | Jan 2001 | WO |
WO 0103641 | Jan 2001 | WO |
WO 0103642 | Jan 2001 | WO |
WO 0105334 | Jan 2001 | WO |
WO 0110313 | Feb 2001 | WO |
WO 0110314 | Feb 2001 | WO |
WO 0112104 | Feb 2001 | WO |
PCTUS0128360 | Mar 2001 | WO |
WO 0113839 | Mar 2001 | WO |
WO 0113908 | Mar 2001 | WO |
WO 0128433 | Apr 2001 | WO |
WO 0130266 | May 2001 | WO |
WO 0145590 | Jun 2001 | WO |
WO 0149213 | Jul 2001 | WO |
WO 0152775 | Jul 2001 | WO |
WO 0154585 | Aug 2001 | WO |
WO 0154625 | Aug 2001 | WO |
WO 0154685 | Aug 2001 | WO |
PCTUS0106958 | Sep 2001 | WO |
WO 0166190 | Sep 2001 | WO |
WO 0174271 | Oct 2001 | WO |
PCTNZ0100092 | Nov 2001 | WO |
WO 0189366 | Nov 2001 | WO |
WO 0195786 | Dec 2001 | WO |
WO 0205884 | Jan 2002 | WO |
WO 0222072 | Mar 2002 | WO |
WO 0232333 | Apr 2002 | WO |
WO 0234322 | May 2002 | WO |
WO 0238038 | May 2002 | WO |
WO 0247575 | Jun 2002 | WO |
WO 02056794 | Jul 2002 | WO |
WO 02064045 | Aug 2002 | WO |
WO 02064190 | Aug 2002 | WO |
WO 02069823 | Sep 2002 | WO |
WO 02094087 | Nov 2002 | WO |
WO 03022124 | Mar 2003 | WO |
WO 03030975 | Apr 2003 | WO |
WO 03003946 | May 2003 | WO |
WO 03034927 | May 2003 | WO |
WO 03041779 | May 2003 | WO |
WO 03047468 | Jun 2003 | WO |
WO 03078579 | Sep 2003 | WO |
WO 03088820 | Oct 2003 | WO |
WO 03099164 | Dec 2003 | WO |
WO 2004010845 | May 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20090205667 A1 | Aug 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09951105 | Sep 2001 | US |
Child | 10847554 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10847554 | May 2004 | US |
Child | 12428287 | US |